Last reviewed · How we verify
Single-Dose Fasting In Vivo Bioequivalence Study of Metolazone Tablets (10 mg; Mylan) and Zaroloxyn® Tablets (10 mg; Celltech) in Healthy Volunteers
The objective of this study was to investigate the bioequivalence of Mylan metolazone 10 mg tablets to Celltech Zaroxolyn® 10 mg tablets following a single, oral 10 mg (1 x 10 mg) dose administration under fasting conditions.
Details
| Lead sponsor | Mylan Pharmaceuticals Inc |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 56 |
| Start date | 2004-02 |
| Completion | 2004-03 |
Conditions
- Healthy
Interventions
- Metolazone Tablets 10 mg
- Zaroloxyn® Tablets 10 mg
Primary outcomes
- Bioequivalence — within 30 days
Countries
United States